Weight loss in Huntington disease increases with higher CAG repeat number

Neurology

Volumn 71, Issue 19, 2008, Pages 1506-1513

  Aziz, N A ^a   Van Der Burg, J M M ^b   Landwehrmeyer, G B ^c   Brundin, P ^b   Stijnen, T ^a   Roos, R A C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTIN; PLACEBO; RILUZOLE; HD PROTEIN, HUMAN; HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; BODY MASS; BODY WEIGHT; CALORIC INTAKE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; HUMAN; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; ADULT; AGED; ANIMAL; C57BL MOUSE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE MODEL; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TRANSGENIC MOUSE; TRINUCLEOTIDE REPEAT;

ADULT; AGED; ANIMALS; BODY MASS INDEX; BODY WEIGHT; DISEASE MODELS, ANIMAL; ENERGY INTAKE; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MIDDLE AGED; NERVE TISSUE PROTEINS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PLACEBOS; RILUZOLE; TRINUCLEOTIDE REPEATS; WEIGHT LOSS;

EID: 56149125562     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000334276.09729.0e     Document Type: Article

References (40)

1. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Harper P. Huntington's Disease. London: W.B. Saunders Company Ltd; 1996.
3. Djousse L, Knowlton B, Cupples LA, Marder K, Shoulson I, Myers RH. Weight loss in early stage of Huntington's disease. Neurology 2002;59:1325-1330.
4. Farrer LA, Meaney FJ. An anthropometric assessment of Huntington's disease patients and families. Am J Phys Anthropol 1985;67:185-194.
5. Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington's disease patients compared with matched controls. Med J Aust 1981;1:407-409.
6. Trejo A, Tarrats RM, Alonso ME, Boll MC, Ochoa A, Velasquez L. Assessment of the nutrition status of patients with Huntington's disease. Nutrition 2004;20:192-196.
7. Menalled LB, Chesselet MF. Mouse models of Hunting-ton's disease. Trends Pharmacol Sci 2002;23:32-39.
8. Nance MA, Sanders G. Characteristics of individuals with Huntington disease in long-term care. Mov Disord 1996; 11:542-548.
9. Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington's disease. Arch Neu-rol 1991;48:800-804.
10. Aziz NA, Swaab DF, Pijl H, Roos RA. Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington's disease: clinical consequences and therapeutic implications. Rev Neurosci 2007;18:223-251.
11. Morales LM, Estevez J, Suarez H, Villalobos R, Chacin DB, Bonilla E. Nutritional evaluation of Huntington disease patients. Am J Clin Nutr 1989;50:145-150.
12. Trejo A, Boll MC, Alonso ME, Ochoa A, Velasquez L. Use of oral nutritional supplements in patients with Hunting-ton's disease. Nutrition 2005;21:889-894.
13. van der Burg JM, Bacos K, Wood NI, et al. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008;29:41-51.
14. Mochel F, Charles P, Seguin F, et al. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS ONE 2007;2:e647.
15. Goodman AO, Murgatroyd PR, Medina-Gomez G, et al. The metabolic profile of early Huntington's disease: a combined human and transgenic mouse study. Exp Neurol 2008;210:691-698.
16. Weydt P, Pineda VV, Torrence AE, et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006;4:349-362.
17. Gaba AM, Zhang K, Marder K, Moskowitz CB, Werner P, Boozer CN. Energy balance in early-stage Huntington disease. Am J Clin Nutr 2005;81:1335-1341.
18. Pratley RE, Salbe AD, Ravussin E, Caviness JN. Higher sedentary energy expenditure in patients with Huntington's disease. Ann Neurol 2000;47:64-70.
19. Hamilton JM, Wolfson T, Peavy GM, Jacobson MW, Corey-Bloom J. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry 2004;75:209-212.
20. Mahant N, McCusker EA, Byth K, Graham S. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092.
21. Sawa A, Wiegand GW, Cooper J, et al. Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat Med 1999;5:1194-1198.
22. Seong IS, Ivanova E, Lee JM, et al. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 2005;14:2871-2880.
23. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Ri-luzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62:262-272.
24. Huntington Study Group. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-142.
25. Siesling S, van Vugt JP, Zwinderman KA, Kieburtz K, Roos RA. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998;13:915-919.
26. Fitzmaurice GM, Laird NM, Ware JH. Applied longitudinal analysis. Hoboken, NJ: John Wiley & Sons, Inc.; 2004.
27. Andrew SE, Goldberg YP, Kremer B, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet 1993;4: 398-403.
28. Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
29. Rosenblatt A, Margolis RL, Becher MW, et al. Does CAG repeat number predict the rate of pathological changes in Huntington's disease? Ann Neurol 1998;44:708-709.
30. Rosas HD, Goodman J, Chen YI, et al. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 2001;57:1025-1028.
31. Rosenblatt A, Liang KY, Zhou H, et al. The association of CAG repeat length with clinical progression in Huntington disease. Neurology 2006;66:1016-1020.
32. Ruocco HH, Bonilha L, Li LM, Lopes-Cendes I, Cendes F. Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 2008;79:130-135.
33. Jenkins BG, Andreassen OA, Dedeoglu A, et al. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. J Neurochem 2005;95:553-562.
34. Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000;48:72-76.
35. Saft C, Zange J, Andrich J, et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005;20:674-679.
36. Rosenblatt A, Abbott MH, Gourley LM, et al. Predictors of neuropathological severity in 100 patients with Huntington's disease. Ann Neurol 2003;54:488-493.
37. Petersen A, Bjorkqvist M. Hypothalamic-endocrine aspects in Huntington's disease. Eur J Neurosci 2006;24: 961-967.
38. Aziz A, Fronczek R, Maat-Schieman M, et al. Hypocretin and melanin-concentrating hormone in patients with Huntington disease. Brain Pathol 2008;18:474-483.
39. Lee JM, Ivanova EV, Seong IS, et al. Unbiased gene expression analysis implicates the huntingtin polyglutamine tract in extra-mitochondrial energy metabolism. PLoS Genet 2007;3:e135.
40. Van Raamsdonk JM, Gibson WT, Pearson J, et al. Body weight is modulated by levels of full-length Huntingtin. Hum Mol Genet 2006;15:1513-1523.